Sexualised drug use in the United Kingdom (UK): A review of the literature by Edmundson, C et al.
 Edmundson, C, Heinsbroek, E, Glass, R, Hope, V, Mohammed, H, White, M and 
Desai, M
 Sexualised drug use in the United Kingdom (UK): A review of the literature
http://researchonline.ljmu.ac.uk/8440/
Article
LJMU has developed LJMU Research Online for users to access the research output of the 
University more effectively. Copyright © and Moral Rights for the papers on this site are retained by 
the individual authors and/or other copyright owners. Users may download and/or print one copy of 
any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. 
You may not engage in further distribution of the material or use it for any profit-making activities or 
any commercial gain.
The version presented here may differ from the published version or from the version of the record. 
Please see the repository URL above for details on accessing the published version and note that 
access may require a subscription. 
For more information please contact researchonline@ljmu.ac.uk
http://researchonline.ljmu.ac.uk/
Citation (please note it is advisable to refer to the publisher’s version if you 
intend to cite from this work) 
Edmundson, C, Heinsbroek, E, Glass, R, Hope, V, Mohammed, H, White, M 
and Desai, M (2018) Sexualised drug use in the United Kingdom (UK): A 
review of the literature. International Journal of Drug Policy. ISSN 0955-3959 
LJMU Research Online
 1 
 
Sexualised drug use in the United Kingdom (UK): A review of the 
literature 
Claire Edmundsona, Ellen Heinsbroeka, Rachel Glassa, Vivian Hopea,b, Hamish Mohammeda, Martin 
Whitec, Monica Desaid  
 
a. HIV & STI Department, National Infection Service, Public Health England, 61 Colindale Avenue, 
London, NW9 5EQ, United Kingdom 
b. Public Health Institute, Liverpool John Moores University, 2nd Floor Henry Cotton Campus, 15-21 
Webster Street, Liverpool L3 2ET, United Kingdom 
c. Alcohol, Drugs and Tobacco, Health Improvement, Public Health England, Skipton House, 80 
London Road, London SE1 6LH, United Kingdom 
d. National Institute for Health and Care Excellence, Level 1A, City Tower, Picadilly Plaza, 
Manchester M1 4BT, United Kingdom 
 
 
 
Corresponding author: 
Mrs Claire Edmundson 
Blood Borne Virus Team, HIV & STI Department 
National Infection Service, Public Health England 
61 Colindale Avenue, London, NW9 5EQ, United Kingdom 
Claire.Edmundson@phe.gov.uk 
Tel: 020 8327 6985 
 2 
 
Sexualised drug use in the United Kingdom (UK): a review of the literature 
Keywords: Sexualised drug use; Chemsex; Men who have sex with men; Homosexual; Slamming;  
Slamsex 
 
Abstract  
Background 
Sexualised drug use (SDU) refers to the use of drugs in a sexual context. This includes ‘Chemsex’- 
the use of drugs (specifically crystal methamphetamine, GHB/GBL and mephedrone) before or during 
planned sexual activity to sustain, enhance, disinhibit or facilitate the experience. Here we aimed to 
synthesise available UK prevalence data for Chemsex, SDU and the use of Chemsex drugs in an 
undefined context (CDU) in men who have sex with men (MSM). 
 
Methods 
Papers published between January 2007 and August 2017 reporting Chemsex, SDU and/or Chemsex 
drug use (CDU) prevalence in MSM were identified through PubMed. Citations were searched for 
further eligible publications. We also conducted a review of national surveillance data, extracting 
prevalence data for Chemsex, SDU or CDU. Synthesized data were then assessed to determine the 
time at which these drugs were taken, in this case just prior to or during sexual activity (event-level). 
Results  
Our search identified 136 publications, of which 28 were included in the final data synthesis. Three of 
the four surveillance systems assessed provided SDU or CDU data in MSM. Few publications 
included event-level data for Chemsex (n=4), with prevalence estimates ranging from 17% among 
MSM attending sexual health clinics (SHC) to 31% in HIV-positive MSM inpatients. Prevalence 
estimates for SDU (n=7 publications) also varied considerably between 4% in MSM receiving HIV 
care to 41% among MSM attending SHC for HIV post-exposure prophylaxis (PEP). Eighteen 
publications provided data for CDU.  
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Conclusion 
Prevalence estimates varied considerably due to differences in the definition used and population 
assessed. Standardised definitions and studies with representative national samples of MSM are 
required to improve our understanding of the extent of Chemsex and its associated risks. Longitudinal 
event-level data for SDU and Chemsex are needed to monitor impact of interventions. 
 
Word Count: 287 
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Box 1:  Glossary  
BBV: Blood-borne viruses including Hepatitis B, Hepatitis C and HIV.  
cAI: Condomless anal intercourse. 
Chemsex: The use of drugs (particularly methamphetamine, GHB/GBL and mephedrone) before or 
during planned sexual activity to sustain, enhance, disinhibit or facilitate the experience. 
Chemsex Drug Use (CDU): The use of any of the Chemsex drugs (mephedrone, methamphetamine, 
GHB/GBL) in an undefined context. 
Club Drugs: Drugs that are usually taken in nightclubs or party environments. Club drugs include; 
scatty (MDMA), ketamine, cocaine, amphetamine and the Chemsex drugs, though definitions vary 
significantly. 
GUMCAD surveillance system: GenitoUrinary Medicine Clinic Activity Dataset. A mandatory 
reporting system providing data on sexual health service provision and sexually transmitted infection 
diagnoses from all sexual health services in England. 
Event-level Data: Data specific to the time at which the drugs were taken, in this case just prior to or 
during sexual activity. 
LGBT: Lesbian, gay, bisexual or transgender individuals. 
MSM: Men who have sex with men. 
NDTMS: National Drug Treatment Monitoring System; collects data on the reported problematic 
substance use of clients attending to treatment for drug addiction. 
Party and Play (PnP): Another term for Chemsex which is commonly used in Australia and the 
United States of America.   
PEP: Post –exposure prophylaxis; any preventative medical treatment started immediately after 
exposure to HIV in order to prevent infection and development of disease. 
PrEP: Pre-exposure prophylaxis; any preventative medical treatment taken prior to exposure to HIV in 
order to prevent infection and development of disease. 
Recall Period: The period assessed for the involvement in Chemsex, SDU or CDU. 
Sexualised Drug Use (SDU): The use of illicit drugs just before or during sexual activity. 
Sexual Health Clinic (SHC): Clinics specializing in the prevention and treatment of sexually 
transmitted infections.  
Slamming:  The injection of Chemsex drugs during Chemsex, also known as ‘Slamsex’. 
STI: Sexually transmitted infection. 
UAM Survey of PWID: Unlinked anonymous survey of people who inject drugs. A national survey 
monitoring BBV prevalence in people who inject drugs (PWID) recruited from England, Wales and 
Northern Ireland. This survey recruits individuals who have ever injected drugs, collecting data on 
injecting and non-injecting modes of drug use. 
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Introduction: 
The relationship between sex and drug use is long established, however the use of drugs in sexual 
contexts (sexualised drug use) has potential implications for public health. Sexualised drug use (SDU) 
has  been associated with risky sexual behaviours (Digiusto & Rawstorne, 2013; Hegazi et al., 2017; 
Nodin, Valera, Ventuneac, Maynard, & Carballo-Dieguez, 2011; Weatherburn, Hickson, Reid, Torres-
Rueda, & Bourne, 2017), increasing the likelihood of participation in condomless sex (Weatherburn et 
al., 2017) and thus the risk of sexually transmitted infection (STI) or blood borne virus (BBV) 
transmission (Olufon & Cathcart, 2016; Ottaway, Finnerty, Amlani, et al., 2017; Page & Nelson, 2016). 
Although not all SDU is problematic, recently emerging patterns of SDU among men who have sex 
with men (MSM) are a cause for concern and have been identified as a public health priority in a 
number of countries (EMCDDA, 2017; Heiligenberg et al., 2012; Parsons, Lelutiu-Weinberger, Botsko, 
& Golub, 2014).  
Patterns of drug use among MSM have changed over the past decade (Ahmed et al., 2016; Adam 
Bourne et al., 2015; Moncrief, 2014) with a notable shift from ‘club drugs’ such as cocaine and 
ecstasy to the use of drugs associated with ‘Chemsex’, namely mephedrone, GHB/GBL, 
methamphetamine, and to a lesser extent, ketamine. These drugs are often, though not exclusively, 
used in a sexual context as they act to increase sexual arousal and performance (Ahmed et al., 2016; 
Melendez-Torres & Bourne, 2016) whilst encouraging disinhibition. As a result, risk-reduction 
precautions and intentions to practise safer-sex can often be overruled (Knoops, Bakker, Bodegom, & 
Zantkuijl, 2015). 
‘Chemsex’, the use of drugs (particularly methamphetamine, GHB/GBL and mephedrone) before or 
during planned sexual activity to sustain, enhance, disinhibit or facilitate the sexual experience, also 
referred to as ‘Party and Play’ (Melendez-Torres et al., 2016), has been linked to various health 
harms in a subset of MSM. Chemsex facilitates engagement in lengthy and condomless sex sessions 
with multiple partners often of unknown serostatus and unknown HIV treatment status, thereby 
increasing exposure to HIV and multiple STIs. Sexual behaviours such as fisting (ano-brachial 
intercourse), anilingus (ano-oral sex) and scat play (Gilbart et al., 2015) can place an individual at 
greater risk of BBVs and gastrointestinal (GI) infections. One such GI infection, Shigella flexneri 
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subtype 3a, has been linked with sexual transmission among MSM during a UK outbreak (Gilbart et 
al., 2015).  
Although it is difficult to determine whether individuals engaged in Chemsex are just as likely to take 
sexual risks if they were not under the influence of the drugs  (Race, Lea, Murphy, & Pienaar, 2016), 
there is some evidence of SDU and CDU’s causal association with riskier sexual behaviours (Colfax 
et al., 2005; Melendez-Torres, Hickson, Reid, Weatherburn, & Bonell, 2017). MSM participating 
Chemsex were found to be five times more likely to report more than six sexual partners in the last 
three months, three times as likely to report use of post-exposure prophylaxis (PEP) and ten times as 
likely to report group sex, when compared to those not participating in Chemsex (Hegazi et al., 2017). 
As some Chemsex drugs can be injected, a practice referred to as “Slamming”, there is the possibility 
for further exposure to BBVs via injection (Kirby & Thornber-Dunwell, 2013; Melendez-Torres & 
Bourne, 2016).  
Among MSM in the United Kingdom (UK) SDU is well described, however few studies are designed 
solely for the collection of data for Chemsex. Internationally however the prevalence of Chemsex 
among MSM is difficult to determine. Although some data are available (Lea, Reynolds, & De Wit, 
2011; Wei, Guadamuz, Lim, Huang, & Koe, 2012), these data are often not specific to drug use just 
prior to or during sexual activity (“event-level data”) or the MSM population due in part to stigma and 
discrimination limiting collection of robust data (Melendez-Torres & Bourne, 2016). Data for Chemsex 
prevalence and associated health harms among other lesbian, gay, bisexual and transgender (LGBT) 
and heterosexual communities are less frequently captured, though some data are emerging 
(Beddoes, Sheikh, Khanna, & Francis, 2010; Moncrief, 2014).   
Understanding the extent of the population at risk is essential for determining harms and developing 
best practice. We therefore aimed to synthesize available evidence in order to better understand the 
prevalence of Chemsex in MSM in the UK. Evidence was identified through a review of published 
evidence and examination of national surveillance data. In our review, we distinguish between three 
forms of substance use: SDU, Chemsex, and the context-independent reporting of Chemsex drug use 
(CDU) (Box 1). Due to the heterogeneous nature of SDU internationally, this review includes UK data 
only, to explore consistency of measurement and to highlight gaps in the available knowledge. 
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Methods: 
Our review of available prevalence data for Chemsex, SDU and CDU in the UK consisted of two 
parts; a scoping literature review and synthesis of available national surveillance data. 
 
Literature Review: 
A scoping literature review was conducted using PubMed. We limited the search to identify studies 
published between January 2007 and 11th August 2017 (the date of this review) which contained UK 
data. Our review focused on MSM exclusively as, although participation in SDU is not limited to this 
group (Mayer, Colfax, & Guzman, 2006), MSM are noted to be at greater risk of the negative 
outcomes of SDU including transmission of BBVs (HIV and hepatitis B and C) (Ireland et al., 2017; 
Turner et al., 2006) particularly due to sexual risks. 
 
Our search included a combination of terms associated with; ‘Chemsex’ or ‘sexualised drug use’, 
‘men who have sex with men’ and the main Chemsex drugs (see Appendix 1, 2 for search strategy).  
A full title screen was conducted removing irrelevant or duplicate articles. Shortlisted titles underwent 
an abstract review. Full papers were shortlisted and reviewed using the eligibility criteria below. 
Publications were included if they contained any prevalence data on Chemsex, SDU and/or the use of 
any Chemsex drug (mephedrone, GHB/GBL or crystal methamphetamine; CDU) (see Box 1). As poly-
drug use is common among MSM reporting CDU (Li & McDaid, 2014), several other substances can 
be used alongside Chemsex drugs, the most common of these secondary drugs is ketamine (A. 
Bourne, Reid, Hickson, Torres-Rueda, & Weatherburn, 2014).  Due to this, and ketamine’s popularity 
among MSM internationally, ketamine prevalence data were included in the data synthesis despite 
the drug not being included in the current UK definition of Chemsex. Publications were excluded if 
they were; non-English language, non-human or based on non-UK data.  Additional publications were 
found through reviewing citations of included papers. 
 
 
National Surveillance Data: 
Available data from Public Health England’s national surveillance systems were extracted to provide a 
representative data source. National data were included in the synthesis if they contained any 
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prevalence data for Chemsex, SDU or CDU specific to MSM in England. National datasets reviewed 
included; a drug treatment monitoring surveillance system (Public Health England, 2017a), a survey 
monitoring BBV prevalence in people who inject drugs (Public Health England, 2017b), a pilot of an 
enhancement to the national sexually transmitted infection surveillance system (Public Health 
England, 2015a) and a survey collecting data on crime in England and Wales (Home Office Statistics, 
2016). 
 
Synthesis of Prevalence Data: 
Prevalence data from eligible publications were extracted and reviewed to determine as to whether 
they were to event-level (see Box 1). Data were reported by data type (Chemsex, SDU or CDU) 
alongside details of the population assessed, urban/rural locality and recall period (e.g. use in the last 
month) (Table 1-4). In order to provide context to the data, the purpose of the included studies, the 
study design, Chemsex definition used and population assessed (sample size, average age, HIV 
status) were summarized (Appendix 3).  
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Results: 
 
1. Literature review: 
Our search identified 136 publications (Figure 1). From these 51 were excluded as they; were 
published >10 years ago (n=46) or were not written in English (n=5). Full texts were then assessed 
and 69 publications were excluded as they; contained no prevalence data (n=22), contained duplicate 
data already published elsewhere (n=2) and/or contained data not specific to MSM (n=2) or the UK 
(n=43).  
 
Eligible publications identified in the literature search (n=16) were then included alongside any found 
through reviewing citations (n=12), into a final data synthesis from 28 eligible publications (Table 1-3).  
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Table 1   Summary of available data for the prevalence of sexualised drug use among MSM in the UK  
 
Table 2   Summary of available data for the prevalence of Chemsex among MSM in the UK  
 
Table 3   Summary of available data for the context independent prevalence of Mephedrone, 
Methamphetamine, GHB/GBL (CDU) and Ketamine β use among MSM in the UK 
 
1.1 Overview of the available published data: 
Of the 28 eligible publications, 7 reported data for SDU (Table 1), 4 for Chemsex (Table 2) and 23 for 
CDU (Table 3), the majority of data were cross-sectional from surveys or case-control studies, with 
only two studies providing longitudinal data (Appendix 3). Despite ketamine being included in the 
search criteria alongside the Chemsex drugs, no eligible publications reported prevalence data for the 
use of ketamine alone. 
 
UK prevalence data captured through these 28 eligible publications were based on sample sizes 
ranging from 12 to 16,565 MSM (Appendix 3).  For 16 of these publications, collection of prevalence 
data for Chemsex, SDU or CDU among MSM was reported to be the main aim of the study. The 
remaining studies (n=11) captured prevalence data as an aside to their main aim; to describe factors 
for BBV acquisition (HIV n=2, HCV n=2), to describe factors for STI acquisition (n=1), as a response 
to a Shigella outbreak (n=2), for service improvement (n=4) or to assess baseline characteristics for a 
intervention (n=1) (Appendix 3).  
 
Most publications captured data on both HIV-positive and negative MSM (n=18), four studies focused 
on HIV–positive MSM and three on HIV-negative MSM alone.  The majority of data were collected 
from urban areas (n=18), with the remainder providing data from both urban and rural localities. No 
studies collected data from exclusively rural locations. The majority of data were collected through 
clinic settings (n=19), spread between sexual health clinics (n=12), HIV clinics (n=1), joint HIV and 
sexual health clinics (n=4) and LGBT drug and alcohol clinics (n=2). Collection of data from 
community settings or outreach was in the minority (n=2), however online data collection was more 
common (n=7). Prevalence data were collected for a range of recall periods with some publications 
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providing data for multiple time frames or contexts. Recall periods assessed included both time frame 
(current involvement (n=3), participation in the last; week (n=1), two weeks (n=1), month (n=6), three 
months (n=6), year (n=8), and lifetime (n=9) or consistent (n=1) participation) and context driven 
(most recent CAI (n=1) or reason for clinic presentation (n=2)) periods (Table 1,2,3).  
 
2. A review of the national surveillance data: 
Four national surveillance systems were assessed for Chemsex, SDU or CDU prevalence data, three 
of which contained relevant data and were included in the synthesis. Annual data from the Crime 
Survey in England and Wales (Home Office Statistics) was excluded from the synthesis as sexuality 
data were not collected. Currently little prevalence data for either SDU (n=1) or CDU (n=3) among 
MSM is captured through national surveillance, with none of the surveillance systems capturing the 
prevalence of Chemsex in this population (Table 4).   
 
Table 4   Summary of available national surveillance data for Chemsex, SDU or CDU among MSM in 
the UK 
 
2.1 Data Sources: 
i) National Drug Treatment Monitoring System (NDTMS): 
A national surveillance system monitoring problematic drug use in those attending treatment for drug 
dependency  (Public Health England, 2017a) captures data on the proportion of those presenting to 
treatment citing problematic use of GHB/GBL and amphetamines, as well as self-reported sexual 
orientation. Prior to the 2016-2017 reporting period sexuality was not a mandatory field, so 
completion varied substantially between regions according to local practice. As this data is not 
currently collected to event-level, it can only be utilised to determine the prevalence of CDU among 
gay and bisexual men and not Chemsex or SDU specifically. 
 
ii) Genitourinary Medicine Clinic Activity Dataset (GUMCAD) pilot: 
A pilot of a behavioural enhancement to routine STI surveillance through GUMCAD was conducted 
for a consecutive 8-week period at each of 5 sexual health clinics (SHCs) across England in 2015 and 
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2016 (Public Health England, 2015a). This provided data on SDU to event-level during last sex as 
well as CDU prevalence. Data were collected on self-reported sexual risk (same- or different sex 
partners). The anticipated national rollout for this new version of GUMCAD is in 2018. Once 
established, this enhanced surveillance system will allow for longitudinal monitoring of behaviour and 
associated biological outcomes. 
 
iii) Unlinked Anonymous Survey of People Who Inject Drugs : 
Data from a national survey monitoring trends in injecting drug use among drug service attendees 
(Public Health England, 2017b) were collated to determine prevalence of specific drug use and 
injection, namely mephedrone and ketamine, among male participants reporting to; 1) have ever 
injected a drug  2) have had sex with a man (MSM) in the last year. Historic data are available since 
the addition of mephedrone to the survey in 2013. As this survey collects data on both injecting and 
non-injecting drug use among people reporting to have ever injected drugs, it provides insight into the 
prevalence of CDU and injected CDU and allows monitoring of trends over time. This survey did not 
capture any data on the use of other Chemsex drugs (GHB/GBL and methamphetamine) and did not 
capture drug use to event-level at the time of this review however recent adaptations mean that this 
data will be available from 2018 onwards. 
 
3. Data Synthesis: 
Prevalence estimates for the extent of SDU, Chemsex and CDU varied considerably depending on 
the location, timeframe and population assessed (Table 1, 2, 3 and 4, Appendix 3). Prevalence 
estimates for SDU, Chemsex and CDU are presented separately below, as is the extent of this data 
which is available to event-level (see Box 1).  
 
3.1 Sexualised drug use prevalence: 
Seven of the 28 eligible publications and only one of the national surveillance systems (GUMCAD) 
reported SDU data to event-level. The majority of these recruited both HIV-positive and negative 
MSM (n=5) from clinic settings (n=6) in exclusively urban areas (n=5). Prevalence estimates for SDU 
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among MSM were mainly collected prospectively (n=4) and range from 4% to 43% depending on the 
population assessed (Table 1, Appendix 3).  
 
Across the four publications and single national surveillance system reporting routine SHC 
attendances by both HIV-positive and HIV-negative MSM, the median prevalence of reported SDU in 
was 23%, however data captured were based on different recall periods (Table 1). One study found 
that of the 1,000 MSM routinely attending six SHCs in England, 12% reported SDU in the last 3 
months. Cross-sectional data captured through two studies recruiting MSM attending to SHCs in 
North West England found similar proportions of MSM attendees reporting SDU in the last year (23% 
and 24%). A retrospective case-control study of 247 MSM attending to SHC in South East England 
found a similar proportion (23%) reported current SDU. However when this study accounted for a 
current STI diagnosis as a marker of risk behaviour, SDU prevalence in this population rose from 16% 
(no STI) to 31% (STI diagnosis). National surveillance during the 2015-16 GUMCAD pilot captured a 
higher prevalence of SDU in routine SHC attendances, with 43% of the 152 MSM reporting any illicit 
drug use in the last three months disclosing SDU during their last sexual encounter (event-level).  
 
When reporting the prevalence of SDU among MSM attending to SHC for post-exposure prophylaxis 
(PEP), a high prevalence of SDU was identified through a case note review. This study found that 
41% of men attending in 2015 reported SDU during the PEP risk event, an increase  from 18% in 
2013-14, however the size of the sample reviewed was limited (2015: n=101, 2013-14: n=51). 
Lifetime reporting of SDU amongst HIV-positive MSM was found to be much lower at just 4% in a 
retrospective case note review of attendees to a joint HIV and SHC, though this too was limited by a 
small samples size (n=85) and may be subject to bias due to the retrospective nature of data 
collection.   
 
Encounter level data were collected through a yearlong community based survey, where MSM were 
asked to report their last condomless anal intercourse (cAI) session with only one sexual partner in 
five waves of online data collection. Of the 6,714 encounters reported by the 2,142 MSM surveyed, 
43% involved SDU.  
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3.2 Chemsex prevalence: 
Limited event-level data were available for Chemsex prevalence (n=4), with only three cross-sectional 
and one case control study reporting Chemsex prevalence data (Table 2, Appendix 3) and none of 
the national surveillance systems (Table 4). As the majority of the control group in the case control 
study were non-MSM, only prevalence data from the cases were included in the data synthesis.  Of 
the included publications, two captured data on MSM attendees to London based HIV and SHCs and 
two interviewed MSM diagnosed with Shigella spp., across England and Wales during two outbreak 
periods. 
Prevalence estimates for current Chemsex range from 17% among MSM attending SHC to 31% in 
HIV positive MSM admissions to a London clinic. A higher proportion was noted in MSM recently 
diagnosed with Shigella (62% & 75%), however, as data were collected as a result of a Shigella 
outbreak, sample sizes were small (n= 34, n=12) and findings may be bias by the distinct population 
addressed. There was variation in the Chemsex definition used in these studies (Appendix 3), with 
two studies including secondary drugs such as ketamine and cocaine in their definition for Chemsex.   
 
3.3 Chemsex drug use prevalence: 
Twenty three studies and three national data sources reported participants’ use of various drugs 
associated with Chemsex, not necessarily in a sexual context, which can be used as a proxy for 
Chemsex behaviour.  
Mephedrone appeared to be the most common Chemsex drug reported by MSM in the UK, with 
GHB/GBL only becoming more popular when HIV-positive MSM are exclusively or disproportionately 
recruited. Similarly, mephedrone remained the most popular drug used in the last 3 months (36%) 
among HIV-negative MSM recruited through a trial for the HIV PrEP (“PROUD” study), followed by 
GHB/GBL (31%) and finally methamphetamine which was reported by the fewest number of men 
(18%). The prevalence of ketamine use varied between studies, with nine studies finding it to be the 
most frequently reported and four studies listing it as the least frequently reported when compared to 
the three Chemsex drugs. 
During the 2015-16 reporting period, NDTMS found 22% of gay and bisexual men presenting to 
treatment for drug addiction reported problematic use of GBL and 34% reported problematic use of 
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amphetamine. Reported problematic use of these drugs was higher in gay or bisexual men when 
compared to heterosexuals (where 2% reported problematic GBL use and 6% problematic 
amphetamine use), as was the reported rate of injecting among those using non-opiate drugs (19% in 
gay or bisexual men vs 2% in heterosexual men). Among MSM who reported illicit drug use in the last 
three months 16% reported mephedrone, 16% GHB/GBL and 9% Methamphetamine use. The 
Unlinked Anonymous Survey of People Who Inject Drugs collects information on non-injecting and 
injecting use of mephedrone and ketamine in people attending general drug services who report ever 
injecting drugs: during 2013-2016 non-injecting use of mephedrone and ketamine in the last month 
was 15% and 10% respectively among men reporting sex with a man in the last year (injected use 
estimates are reported in section 3.4 below). 
 
Although the preference for mephedrone seemed to be consistent geographically, regional variations 
were seen in the reported use of any of the Chemsex drugs and ketamine. UK data extracted from a 
large international study of over 160,000 MSM, found that within the UK sample (n= 8,291), MSM 
recruited in London were more likely to report the CDU in the last four weeks than those recruited 
outside of London (methamphetamine: 3% vs 1%,  GHB/GBL: 6% vs 2%, Mephedrone: 5% vs 3%,  
Ketamine: 6% vs 4%). Further analysis of this data assessed methamphetamine, mephedrone, 
ketamine and GHB/GBL use by MSM across 44 European cities, and found past four week use to be 
highest in Brighton (16%), Manchester (16%) and London (13%) relative to other European cities. 
Further regional disparity was noted in the Gay Men’s Sex Survey which found methamphetamine 
use among MSM in London to be five times that of outside London (5% vs 1%), with the regional 
variation (London vs outside London) in reported mephedrone and GHB/GBL only slightly less than 
this (mephedrone: 12% vs 3% and GHB/GBL: 8% vs 2%).  
 
3.4 Injection of Chemsex drugs: 
Few publications contained event level prevalence data for the injection of Chemsex drugs amongst 
MSM prior to or during sex (Slamming/Slamsex) (n=3) and no event level data for Chemsex drug 
injection were captured through national surveillance. Prevalence estimates for the injection of 
Chemsex drugs at event level range between 12% in HIV positive MSM and 24% in MSM recently 
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diagnosed with Shigella. When comparing this latter study to a prior Shigella outbreak amongst MSM 
during 2009-10, the prevalence of event level Chemsex drug injection appears  to have increased 
from 16% to 24% (during a 2012-13 outbreak), though both studies were limited by their small sample 
size. One study provided event level data for the injection of the individual Chemsex drugs among 
MSM attending to 6 SHCs in England. In this study, methamphetamine proved the most commonly 
injected Chemsex drug (2%) when compared to mephedrone (0.8%). Non-event-level data for the 
prevalence of ‘club drug’ injection were captured in 2 publications, with prevalence estimates ranging 
from 25% in MSM recruited at four settings in Brighton to 49% in MSM attendees to a London LGBT 
drug and alcohol service.  
 
Prevalence data for the injection of drugs used in Chemsex were captured through one national 
surveillance system; however this data was not captured to event level. National monitoring at general 
drug services through the Unlinked Anonymous Monitoring Survey of People Who Inject Drugs (UAM 
Survey of PWID) found the injection of mephedrone and ketamine in the last month to be 12% and 
6% respectively among MSM attendees during 2013 to 2016, which was higher than the injected use 
of mephedrone and ketamine among non-MSM attendees (5% and 2%) (Heinsbroek, Glass, Tanner, 
Hope, & Desai, in press). Since 2000, an increase in the proportion of males recruited in the survey 
who reported sex with men has been observed (4.4% in 2000/01 to 8.4% in 2014/15), as well as 
altered drug use patterns with increasing stimulant injection and decreasing opiate injection among 
MSM, suggesting ‘slamming’ is now evident among MSM accessing general drug services (Glass, 
Hope, Tanner, & Desai, 2017). 
 
Discussion  
Nationally, subgroups of MSM are participating in Chemsex and SDU, potentially heightening their 
risk of STI or BBV acquisition and other health harms. Understanding the prevalence of Chemsex and 
SDU in MSM is essential in order to better target interventions and monitor their impact. This review 
found that prevalence estimates for Chemsex among MSM in the UK varied greatly, were mainly 
London or urban focused and from clinic settings or as part of an outbreak response. The majority of 
data were limited by the differing definitions and recall periods used, and by a focus on sampling 
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small samples from subgroups of MSM rather than the population as a whole (Table 2, Appendix 3). 
Event-level prevalence estimates for SDU in UK MSM also varied greatly and were mainly from urban 
and clinic based studies (Table 1). Little national representative data is available for SDU among 
MSM, and Chemsex remains uncaptured in any of the national surveillance systems (Table 4).  In 
order to establish the true extent of Chemsex and SDU among MSM, there is requirement to have a 
sample representative both in terms of risk and geography, data which is currently lacking.  
The majority of data related to the extent of Chemsex in the UK MSM population is from studies 
collecting data for CDU as a proxy for Chemsex (Table 3); however the use of these drugs, 
particularly mephedrone, will not always be related to sex.  Although CDU has been found to be 
significantly associated with an STI diagnosis in the last year (Sewell et al., 2017), it is worth noting 
that not all SDU or Chemsex is problematic and it is possible for participation to be non-detrimental to 
health and wellbeing if appropriate precautions are made. 
To our knowledge, this is the first review of its kind, aiming to summarise available data for the 
prevalence of Chemsex among MSM in the UK and highlight gaps which limit its comparability and 
synthesis. It provides a basis from which to build a better understanding of the extent of Chemsex and 
SDU among MSM and advises as to how best to target future data collection. 
Throughout the published literature we found significant variations in the Chemsex definitions used 
(Appendix 3). Chemsex and SDU were frequently referred to interchangeably, with Chemsex 
sometimes being incorrectly defined as ‘sex under the influence of any illicit drug’ (MacRae, Lord, 
Forsythe, & Sherrard, 2017; Melendez-Torres et al., 2017; Mohammed et al., 2016). Variations were 
seen in the drugs included; sometimes solely Chemsex drugs, but often other illicit drugs, such as 
ketamine, cocaine and/or ecstasy (Chan, Wood, & Dargan, 2015; Gilbart, Simms, Gobin, Oliver, & 
Hughes, 2013; Hegazi et al., 2017; Schmidt et al., 2016).  
Chemsex drugs were also included as ‘Club Drugs’, for which definitions were equally as broad and 
inconsistent (Daskalopoulou et al., 2014; Drumright, Patterson, & Strathdee, 2006; Keogh et al., 
2009), with some including LSD, nitrites (poppers), Rohypnol and Viagra in their definition (Drumright 
et al., 2006). Use of a non-standardised definition allows studies to capture poly-drug use, as other 
drug and substances are often used alongside the three Chemsex drugs when engaging in Chemsex 
(A. Bourne et al., 2014).  In order to overcome this distorting effect, studies often collated data on 
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individual drug use. However, this limits comparability as individuals may have reported the use of 
more than one Chemsex drug, making the prevalence estimate for involvement in Chemsex as a 
whole difficult to determine. 
Future data collection should utilise a standardised definition in order to build a strong and 
comparable knowledge base.  For this review we drew upon Public Health England’s definition of 
Chemsex; “the use of drugs before or during planned sexual activity to sustain, enhance, disinhibit or 
facilitate the experience. Chemsex commonly involves crystal methamphetamine, GHB/GBL and 
mephedrone, and sometimes the injecting these drugs as slamming)”(Public Health England, 2015b). 
This definition highlights the key Chemsex drugs and their use at event-level (i.e. prior to or during 
sex), providing the specificity and clarity required to form a strong knowledge base. This definition 
however does not include secondary drugs such as ketamine. This is because the drugs used in 
Chemsex, and related forms of SDU such as Party and Play (Box 1), vary from country-to-country, 
reflecting the availability of substances locally. Therefore, whilst our suggested definition works well in 
the UK, it is likely that definitions for other countries will need to be reflective of local patterns of drug 
use and thus may include different drugs. Further work is therefore required in order to establish a 
unifying definition for international comparisons.  
Comparison between event-level prevalence estimates was hampered by variation the recall periods 
assessed (Table 1-4). Surveys included in this synthesis of UK data used seven different temporal or 
context driven (e.g. last PEP/cAI episode) recall periods. A larger quantity of event-level SDU 
prevalence data was found, however this too is subject to a broad range of prevalence estimates due, 
in part, to variations in the recall periods addressed.  
In the absence of Chemsex or SDU event-level data, CDU can be utilised as a direct proxy for 
Chemsex, though it is worth noting that CDU is not limited to sexual contexts and Chemsex drugs are 
used in a range of other settings.  Mephedrone was the most popular of the Chemsex drugs used 
among MSM in the UK potentially due to its availability, low cost and reliable quality (A. Bourne et al., 
2014), although recent data suggests potential for a recent decline in use (Public Health England, 
2017c). Similar reasons for use are suggested for GHB/GBL, which was more popular in surveys 
where HIV-positive MSM were exclusively or disproportionately recruited. This is especially worrying 
due to the recent observed rise in the number of GHB-associated deaths in London (Hockenhull, 
 19 
 
Murphy, & Paterson, 2016). Ketamine appeared to be as popular if not more popular than 
mephedrone in some studies, however this may reflect the use of both of these drugs being common 
in non-sexual contexts, when compared to the GHB/GBL and methamphetamine. Methamphetamine 
use was markedly lower possibly due to its highly addictive nature and association with slamming, 
although use was higher in London than outside of London and amongst HIV positive individuals.  
The majority of the available event-level data were collected through one-off cross-sectional surveys, 
providing a snap shot of prevalence in the surveyed population at one point in time. Event level data 
were frequently based on small sample sizes and specific sub-populations of MSM, limiting its 
generalisability to the population as a whole. Time-series data or repeated cross-sectional surveys 
using robust measures over time are needed to better understand risks and inform responses. This 
would also allow exploration of the temporal relationship between Chemsex and other risk behaviours 
and a fuller assessment of the relationship between Chemsex or SDU and infections such as HIV or 
STIs. 
Little representative national data for SDU and Chemsex were found, however forthcoming 
adaptations to a national surveillance system of attendees to SHCs (Public Health England, 2015a) 
will allow for the collection of event-level data for SDU, and the monitoring of attendee’s sexual health 
over time. Adaptations to another national surveillance system monitoring individuals attending to 
treatment  for drug addiction (Public Health England, 2017a) will mandate the reporting of sexuality, 
allowing for more easily comparable data over time. Together these will help address the current gaps 
in data from the UK. 
The available prevalence data for Chemsex, SDU and CDU were almost exclusively urban and clinic 
focused. On the occasion that data from rural localities were captured, it was never reported 
independently. London appeared to be the focus for data collection, with seven studies reporting 
exclusively London data and five recruiting from London alongside other urban centres. Data suggest 
Chemsex is more prevalent in London, Manchester and Brighton (Schmidt et al., 2016), however 
anecdotal reports and recent evidence suggesting use of drugs associated Chemsex is common 
across the UK, has resulted in calls for a targeted sexual health response across the UK (Moncrief, 
2014; Wiggins, Mebrahtu, Sullivan, Field, & Hughes, 2016).  
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Available Chemsex and SDU prevalence data was often specific to subpopulations of MSM; some 
assessed MSM engaging in risky sexual behaviours (e.g. cAI), some HIV-positive, some HIV-negative 
and some a mixture of the above. Although determining Chemsex and SDU prevalence in these sub-
groups is important when assessing risk and clinical practice, their diversity and biases make it 
difficult to synthesise data and assess the overall extent of Chemsex.  
Estimates for Chemsex were notably higher in HIV-positive MSM and MSM participating in high risk 
behaviours (cAI) than in those who attended to SHCs. When comparing London based studies, recent 
participation in Chemsex was found to be more prevalent amongst HIV-positive MSM inpatient 
admissions when compared to MSM attending two SHCs (31% vs 17%). Higher prevalence of 
Chemsex in HIV-positive MSM can also be noted in unpublished data (Hibbert et al., In Press; Pufall 
et al., 2016). The high levels of Chemsex among these sub-groups is of concern in the context of the 
possible impact on ART adherence, drug interactions and the subsequent effect on viral load and 
onwards transmission.  
There were several limitations to this scoping review. Firstly, the scope of this review is potentially 
limited by only having searched a single database. Though measures were taken to capture key 
publications by reviewing citations in eligible papers, some publications may have been overlooked 
and therefore not included in the data synthesis. However, as the studies found were heterogeneous 
and subject to bias, it is unlikely that further studies identified through alternative database searching 
would have been sufficient to have overcome these limitations and make a full synthesis possible. 
Secondly, as this was a scoping and not a systematic review, no formal quality assessment was 
conducted on the identified publications. Finally only one reviewer screened and assessed articles for 
eligibility, therefore the inclusion of studies could also have been affected by reviewer bias or 
subjective views.  
This scoping review focused on the use of Chemsex drugs among MSM due to particular concerns 
regarding infection risk in this population. The prevalence of Chemsex in other groups such as women 
who have sex with women, female sex workers or HIV positive or high risk heterosexuals has 
therefore not been examined, even though SDU has been noted in these populations (Marquez, 
Mitchell, Hare, John, & Klausner, 2009; Moncrief, 2014; Paxton, Williams, Bolden, Guzman, & 
Harawa, 2013). 
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Future event-level data specific to the prevalence of Chemsex are required to better understand the 
extent among MSM and other LGBT populations. Use of a standardised Chemsex definition and 
assessment of recency of drug use rather than a specific recall period will allow for easier comparison 
between studies and subpopulations. Robust time-series data from either longitudinal or repeated 
cross-sectional studies are needed in order to better estimate prevalence data, detect changes in 
patterns of drugs use and behaviour over time and monitor the impact of interventions. Future 
collection of data through national surveillance systems should collect or disaggregate data by 
sexuality so as to provide a national and representative data source.  
In conclusion, the extent of sexualised drug use and Chemsex among MSM in the UK remains poorly 
understood with little published national data available.  Evidence for the prevalence of Chemsex and 
SDU at event-level is lacking and limited by reliance on clinic or community cross-sectional surveys 
with differing definitions and sampling methodologies, making comparison difficult.  However 
prevalence estimates for both SDU and Chemsex seem to vary considerably both by HIV status, risk 
behaviour and region. 
 A standardised definition and use of recency of drug use instead of a specific recall period would 
strengthen data collection to allow for a better understanding of the extent of Chemsex, its associated 
risks and the impact of any future interventions.  
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Table 1   Summary of available data for the prevalence of sexualised drug use among MSM in the UK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*
 All MSM attending to clinic.        
$ Data provided is encounter level, 2142 MSM reporting on drug use in 6742 sexual encounters. 
 
Abbreviations: Men who have sex with men (MSM), Sexualised drug use (SDU), Chemsex drug use (CDU), Condomless anal intercourse (cAI), Post Exposure Prophylaxis for Sexual Exposure (PEP), 
Sexual health clinics (SHCs) 
 
 
Study Population assessed  HIV 
status Location 
Recall 
Period 
Prevalence  
SDU Slamsex Event-level  
Ireland   2017 
 
(Ireland et al., 2017) 
Self-complete questionnaire given to MSM 
attending to 4 SHCs between Feb to Dec 2013 Both  
Urban/Rural    
(Greater Manchester)  Last year 
23%   
(432/1920) . Yes: SDU 
MacRae 2017 
 
(MacRae et al., 2017) 
Retrospective case note audit of MSM attending 
for routine HIV care at an integrated HIV and 
SHC during 2015 
HIV 
Positive Urban (Oxford) Ever 
4%               
(3/85) . Yes: SDU 
Melendez-
Torres  2017 
 
(Melendez-Torres et al., 
2017) 
Five waves of online data collection between 
2011 to 2012 recruiting MSM through dating 
websites or as completed previous survey 
Both  Urban/Rural             (online- England only) 
During 
most recent 
cAI session 
43%$ 
(2881/6714) . Yes: SDU 
Mohammed 
2016 
 
(Mohammed et al., 
2016) 
National surveillance of MSM attending to 6 
SHCs across England, August 2013 to April 
2014 
Both  
Urban                 
(London [n=4], 
Southend, Bristol, 
Bedford) 
Last 3 
months 
12%*             
(127/1049) . 
Yes: SDU, CDU 
and injection of 
individual drugs. 
Ottaway 2017 
(a) 
 
(Ottaway, Finnerty, 
Amlani, et al., 2017) 
Cross sectional case-control study including 260 
MSM SHC attendees during a 6 month period in 
2015. Cases were individuals with a diagnosed 
STI. Controls were age matched individuals with 
no STI diagnosis. 
Both  Urban                 (Brighton) Current 
23%         
(58/247) . Yes: SDU 
Ottaway 2017 
(b) 
 
(Ottaway, Finnerty, 
Buckingham, & 
Richardson, 2017) 
Local case note audit of MSM attending to a 
SHC for PEP over two 4 month periods (Nov  
2013 to Feb 2014 and Mar 2015 to Jun 2015) 
HIV 
Negative 
Urban                 
(Brighton) 
During PEP 
episode 
2013-14: 18% 
(9/51)            
2015: 41% 
(41/101) 
. Yes: SDU 
Ward 
 2014 
 
(Ward & Lee, 2014) 
Self -complete questionnaire given to all MSM 
attending to a SHC between April to June 2014 Both  
Urban              
(Manchester) Last year 
24%     
(115/471) . Yes 
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Table 2   Summary of available data for the prevalence of Chemsex among MSM in the UK  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Ketamine is included in the utilised Chemsex definition 
** Slamsex prevalence not specific to Chemsex drugs, defined as the injection of any drug 
*** Inclusion of cocaine and ketamine in the utilised Chemsex definition 
 
Abbreviations: Sexual health clinics (SHCs), Men who have sex with men (MSM). 
 
Study Population assessed HIV 
status Location 
Recall 
Period 
Prevalence 
Chemsex Slamsex Event-level 
Elliot 
2017 
 
(Elliot, Singh, 
Tyebally, Gedela, & 
Nelson, 2017)
 
Opt-out physician administered survey 
completed by all MSM admissions to a HIV 
inpatient unit between Oct 2014 to Jan 2015 
HIV 
Positive 
Urban        
(London) Current 
31%         
(13/42) 
12%         
(5/42) 
Yes:         
Chemsex 
& Slamsex 
Gilbart 
2013 
 
(Gilbart et al., 
2013) 
MSM interviewed after diagnosis with Shigella 
during 2009-11 outbreak Both 
Urban/Rural    
(across 
England & 
Wales) 
Use during 
sexual 
encounters 
75% 
(9/12)* 
16% 
(2/12)** 
Yes:         
Chemsex 
& Slamsex 
Gilbart 
2015 
 
(Gilbart et al., 
2015) 
Sexually active MSM diagnosed with Shigella 
between Oct 2012 to May 2013, face to face 
semi structured interviews 
Both 
Urban/Rural    
(across 
England & 
Wales) 
The two 
weeks prior 
to Shigella 
episode 
62%         
(21/34) 
24%       
(8/34) 
Yes:         
Chemsex 
& Slamsex 
Hegazi 
2017 
 
(Hegazi et al., 
2017) 
Retrospective case note review for MSM 
attendees to two SHCs June 2015 to Jan 2016 Both 
Urban        
(London) Current 
17%***       
(113/655) . 
Yes:         
Chemsex 
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Table 3   Summary of available data for the prevalence of Mephedrone, Methamphetamine, GHB/GBL (CDU) and Ketamine β use among MSM in the UK 
¥ Data from the larger UK wide EMIS sample used as a comparator to this London focused analysis. 
β Ketamine is not included in Public Health England’s definition of Chemsex, however prevalence data for ketamine are reported here for international comparison. 
Table continued on the next page 
Study Population assessed  HIV 
status Location 
Recall 
Period 
Prevalence 
Chemsex drug use Slamsex Event-level  
Bonell        
2009 
 
(Bonell, Hickson, 
Weatherburn, & Reid, 
2009) 
MSM participating in a self-
complete survey distributed 
through 107 community based 
agencies or available online 
through 2007 
Both 
Urban/Rural 
(England, 
Wales, 
Scotland, 
Northern 
Ireland) 
Last Year: 
London * 
Out of 
London ** 
Mephedrone . . 
. No 
Methamphetamine 8% 
*
 
5% ** 
(155/1986) * 
(290/6155) ** 
GHB/GBL . . 
Ketamine ȕ . . 
Bourne      
2014 
 
(A. Bourne et al., 2014) 
Secondary analysis of EMIS data: 
an online survey recruiting MSM 
through gay dating and social 
networking sites across 38 
countries  during the summer of 
2010 
Both 
Urban          
(London: 
Lewisham, 
Southwark 
and Lambeth 
(LSL) 
boroughs) 
LSL:  
Ever          
Last year      
Last four 
weeks          
/              
Use in the 
last four 
weeks: 
London § 
Out of 
London ¥ 
Mephedrone 
27%      
14%     
10%       
5% §       
3% ¥ 
(308/1135)       
(154/1135)       
(114/1135)       
(200/3837) §     
(447/15423) ¥ 
. No 
Methamphetamine 
24%       
14%       
5%         
3% §       
1% ¥ 
(274/1133)       
(160/1133)       
(57/1133)         
(155/3837) §     
(108/15423) ¥ 
GHB/GBL 
30%       
20%       
11%       
6% §       
2%  ¥ 
(337/1124)       
(225/1124)       
(124/1124)       
(211/3837) §     
(247/15423) ¥ 
Ketamine  ȕ 
41.9%       
7%         
5%         
6% §       
4%  ¥ 
(474/1132)       
(76/1132)         
(55/1132)         
(226/3837) §     
(586/15423) ¥ 
Daskalopoulou 
2014 
 
(Daskalopoulou et al., 
2014) 
MSM attending 8 HIV outpatient 
clinics between Feb 2011to Dec 
2012 completed a self-
administered questionnaire 
HIV 
Positive 
Urban 
(Brighton, 
Eastbourne, 
Manchester, 
London) 
Last 3 
months 
Mephedrone 7% (162/2248) 
. No 
Methamphetamine 8% (175/2248) 
GHB/GBL 10%   (220/2248) 
Ketamine  ȕ 13% (280/2248) 
 30 
 
≠
 Drugs included mephedrone, GHB/GBL or methamphetamine 
β Ketamine is not included in Public Health England’s definition of Chemsex, however prevalence data for ketamine are reported here for international comparison. 
 
 
 
 
 
Table continued on the next page 
Dolling      
2016 
 
(Dolling et al., 
2016) 
Sexually active MSM recruited through 13 
SHCs across England to complete a self-
compete questionnaire during the PROUD 
PrEP trial Nov 2012 to April 2014 
HIV 
Negative 
Urban 
(London, 
York, 
Sheffield, 
Manchester, 
Brighton & 
Birmingham) 
Last 3 months 
Mephedrone 36% (197/540) 
. No 
Methamphetamine 18% (98/540) 
GHB/GBL 31% (169/540) 
Ketamine ȕ 16% (89/655) 
Use of ≥1 Chemsex 
drug≠ 44% (231/525) 
Elliot         
2017 
 
(Elliot et al., 
2017) 
Opt out physician administered survey 
completed by all MSM admissions to a HIV 
inpatient unit between Oct '14 to Jan '15 
HIV 
Positive 
Urban        
(London) Current 
Mephedrone 17% (7/42) 
12%       
(5/42) 
Yes: 
Chemsex 
& Slamsex 
Methamphetamine 21% (9/42) 
Ketamine ȕ 5% (2/42) 
GHB/GBL 19% (8/42) 
Fox         
2009 
 
(Fox et al., 
2009) 
All newly diagnosed HIV positive MSM 
attending to SHC Jan 2002 to Jan 2004 who 
completed a structured electronic 
questionnaire at baseline & at 12 week follow 
up 
HIV 
Positive 
Urban        
(London) 
In previous 12 
weeks 
Mephedrone . . 
. No 
Methamphetamine 8% (8/98) 
GHB 29% (28/98) 
Ketamine ȕ 43% (42/98) 
GBL . . 
Hegazi  
2017 
 
(Hegazi et al., 
2017) 
Retrospective case note review for MSM 
attendees to two SHCs June 2015 to Jan 
2016 
Both Urban        (London) Current use 
Mephedrone 11% (70/655) 
. 
Yes: 
Chemsex 
Methamphetamine 7% (46/655) 
Ketamine ȕ 1% (6/655) 
GHB/GBL 9% (57/655) 
 31 
 
β Ketamine is not included in Public Health England’s definition of Chemsex, however prevalence data for ketamine are reported here for international comparison. 
                
 
 
Table continued on the next page 
Hickson  
2016 
 
(Hickson F, 
2014) 
MSM completing the Gay Men’s Sex Survey 
2014: an online open access survey 
completed July to October 2014 
Both Urban/Rural 
Ever            
Last Year         
Last four 
weeks          
/                    
Use in the last 
four weeks:      
London§         
Out of 
London¥ 
Mephedrone 
17%       
11%      
5%         
12% §       
3% ¥ 
(2534/15360) 
(1674/15360) 
(814/15360) 
(458/3951)§        
(365/11409)¥ 
. No 
Methamphetamine 
8%      
5%       
2%      
5% §    
1% ¥ 
(1275/15360) 
(737/15360) 
(307/15360) 
(194/3951)§       
(114/11409)¥ 
. No 
GHB/GBL 
13%       
7%         
3%       
8% §       
2% ¥ 
(1920/15360) 
(998/15360) 
(492/15360) 
(324/3951) §      
(171/11409)¥ 
. 
 
No 
Ketamine ȕ 
20%       
8%         
2%        
. 
§
          
. 
¥
 
(2995/15360) 
(1152/15360) 
(276/15360) 
. 
§ 
          
 . 
¥
 
Use of any of above 
in last 4 weeks 7% (979/14833) 
Hunter 
2014 
 
(Hunter, 
Dargan, 
Benzie, White, 
& Wood, 2014) 
Self-complete questionnaire given to MSM 
attending a SHC in 2 London hospitals over a 
3 month period, July to Sept 2011 
Both Urban        (London) 
Ever            
/                    
Last month 
Mephedrone 24%       3% 
(50/254)         
(4/254) 
. No 
Methamphetamine 17%       1% 
(34/254)         
(3/254) 
GHB 23%       2% 
(48/254)         
(6/254) 
GBL 16%       3% 
(29/254)         
(8/254) 
Ketamine ȕ 34% 4% 
(80/254) 
(9/254) 
Ireland 
2017 
 
(Ireland et al., 
2017) 
Self-complete questionnaire given to MSM 
attending to four SHCs between Feb to Dec 
2013. 
Both 
Urban/Rural    
(Greater 
Manchester) 
In the last year 
Mephedrone 6% (125/2030) 
. Yes: SDU 
Methamphetamine 2% (45/2030) 
GHB 5% (100/2030) 
GBL . . 
Ketamine ȕ . . 
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^ Ever use of club drugs “such as” mephedrone, GBL/GHB or methamphetamine 
∞ Ever injection of club drugs “such as” mephedrone, GBL/GHB or methamphetamine 
β Ketamine is not included in Public Health England’s definition of Chemsex, however prevalence data for ketamine are reported here for international comparison. 
 
Table continued on the next page 
Keogh 
2009 
 
(Keogh et al., 
2009) 
MSM completing the Gay Men’s Sex Survey 
2007: online completion and questionnaire 
distribution by community healthcare workers 
Both Urban/Rural Ever              Last Year 
Mephedrone . . 
. No 
Methamphetamine 10%     5% 
(585/6155)       
(289/6155) 
GHB/L 13%     7% 
(800/6155)    
(430/6155) 
Ketamine ȕ 21%   12% 
(1293/6155) 
(739/6155) 
Kurka 
2015 
 
(Kurka, Soni, & 
Richardson, 
2015) 
MSM attending to four clinical settings: SHC, 
HIV clinic, local NGO and a walk in primary 
care clinic in Brighton, January to March 2014. 
Both Urban/Rural    (Brighton) 
Ever              
/                    
Last month 
Mephedrone 38%     19% 
(94/246)         
(47/246) 
25%∞      
(62/245) No 
Methamphetamine 10%     3% 
(25/246)         
(7/246) 
GHB/GBL 24%     11% 
(59/246)         
(27/246) 
Ketamine ȕ . . 
Use of Club drugs^ 53% (124/246) 
Macdonald 
2008 
 
(Macdonald et al., 
2008) 
MSM attending to 7 SHCs between Sept 2002 
to Oct 2004 were assigned to a case/control 
group based on their HIV status then asked to  
complete a computer assisted self-interview 
Both 
Urban          
(London, 
Manchester, 
Brighton) 
Ever 
Mephedrone . . 
. No 
Methamphetamine 13% (29/232) 
GHB 18% (42/232) 
GBL . . 
Ketamine ȕ 38% (88/232) 
Macdonald 
2014 
 
(Macdonald et al., 
2014) 
MSM attendees (rLGV cases and random 
controls)  to HIV or MSM specialist clinics of 6 
hospitals between Aug 2008 to Dec 2010, who 
participated in a computer assisted self-
interview 
Both 
Urban          
(London 
Brighton 
Glasgow) 
Last 3 months 
Mephedrone . . 
. 
Yes: Sex 
under the 
influence of 
CDU 
Methamphetamine 26% (60/227) 
GHB/GBL 37% (86/227) 
Ketamine . . 
MacRae 
2017 
 
(MacRae et al., 
2017) 
Retrospective case note audit of MSM 
attending for routine HIV care at an integrated 
HIV and SHC during 2015. 
HIV 
Positive 
Urban 
(Oxford) Ever 
Mephedrone 6% (4/63) 
. Yes: SDU 
Methamphetamine 1% (1/63) 
GHB/GBL . . 
Ketamine ȕ . . 
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$Data provided is encounter level, 2142 MSM reporting on drug use over 6742 encounters. 
^  MSM attendees with >1 sexual partner in the last 3 months 
β Ketamine is not included in Public Health England’s definition of Chemsex, however prevalence data for ketamine are reported here for international comparison. 
* Data based on all SHC attendees, not specific to MSM however 94% of the sample who specified gender were gay/bisexual men 
** Club drug injection, not to event-level. Drugs included in ‘club drug’ definition unspecified 
*** ‘Four Chems’ drug category includes ketamine, GHB/GBL, mephedrone and methamphetamine 
Table continued on the next page 
Melendez-
Torres  
2016 
 
(Melendez-Torres et al., 
2016) 
MSM completing the Gay Men’s Sex Survey 
2014: an online open access survey 
available during the summer of 2014 
Both Urban/Rural 
Ever              
Last Year         
Last four weeks    
Last week 
Methamphetamine 
8% (1310/16,565) 
. No 
5% (747/16,565) 
2% (316/16,565) 
1% (161/16,565) 
Melendez-
Torres  
2017 
 
(Melendez-Torres et al., 
2017) 
Five waves of online data collection between 
2011-12 recruiting MSM through dating 
websites or as completed previous survey. 
Both 
Urban/Rural    
(online- 
England 
only) 
During most 
recent cAI 
session$ 
Mephedrone$ . . 
. Yes: SDU 
Methamphetamine$ 1% (72/6455) 
GHB$ 1% (94/6714) 
GBL$ . . 
Ketamine ȕ $ 1.4% (92/6623) 
Mohammed 
2016 
 
(Mohammed et al., 
2016) 
MSM attending to 6 national surveillance 
pilot SHCs across England, August 2013 to 
April 2014 
Both  
Urban          
(London, 
Southend, 
Bristol, 
Bedford) 
Last 3 months 
Mephedrone^ 10% (54/519) 0.8%
^
 
(4/519) Yes: SDU, 
CDU and 
slamming 
of 
individual 
drugs. 
Methamphetamine^ 4% (19/519) 2%
^
              
(8/519) 
GHB/GBL^ 7% (37/519) . 
Ketamine ȕ . . . 
Moncrief 2014 
 
(Moncrief, 2014) 
All clients* attending to Antidote, a London 
based LGBT drug and alcohol support 
service during 2013/14 
. 
Urban          
(London) 
Reason for 
presentation at 
clinic 
Mephedrone 64% 461/720 
49%      
(239/490)
** 
No 
Methamphetamine 51% 373/727 
GHB/GBL 46% 334/726 
Ketamine ȕ 6% 44/758 
Schmidt 2016 
 
(Schmidt et al., 2016) 
EMIS: Anonymous online self-complete 
questionnaire completed by MSM across 38 
countries during June - August 2010 
Both  Urban/Rural (online) Last 4 weeks 
Use of any of the four Chems***:         
. No 
Brighton  16%  (47/290)      
Manchester      16%  (91/586) 
London  13% (631/4816)  
Birmingham 3%  (10/338)  
UK Comparison 4% (340/8291) 
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* Chemsex drugs defined as mephedrone, GHB/GBL or methamphetamine 
β Ketamine is not included in Public Health England’s definition of Chemsex, however prevalence data for ketamine are reported here for international comparison. 
 
Abbreviations:  Men who have sex with men (MSM), Sexualised drug use (SDU), Chemsex drug use (CDU), Condomless anal intercourse (cAI), Post Exposure Prophylaxis for Sexual Exposure (PEP),  
Sexual health clinic (SHC), Rectal Lymphogranuloma Venereum (rLGV) 
 
 
 
 
 
 
 
 
Sewell 
 2017 
 
(Sewell et al., 2017) 
MSM attending to 20 SHCs 
across England between June 
2013 to Nov 2014 were asked 
to complete a self-
administered questionnaire 
HIV Negative 
or 
undiagnosed 
Urban/Rural Last 3 months 
Mephedrone 19% (283/1484) 
. No 
Methamphetamine 6% (95/1484) 
GHB/GBL 12% (178/1484) 
Ketamine ȕ 8% (125/1484) 
Use of  ≥1 Chemsex 
drug* 22% (324/1484) 
Stuart 
2013 
 
(Stuart, 2013) 
All clients attending to 
Antidote, a London based 
LGBT drug and alcohol 
support service during 2012 
. 
Urban          
(London) 
Reason for 
presentation at 
clinic 
Mephedrone . . 
. No 
Methamphetamine . . 
GHB . . 
GBL . . 
Ketamine . . 
Use of ≥1 Chemsex 
drug* 85% . 
Thurtle 2016 
 
(Thurtle et al., 2016) 
All MSM attending to 2 SHCs 
in central London between 
Dec 2013 to March 2014 were 
asked to participate in a self-
complete survey 
. 
Urban          
(London) Ever 
Mephedrone . . 
. No 
Methamphetamine 15% (52/339) 
GHB 19% (64/339) 
GBL 13% (44/339) 
Ketamine ȕ 27% (92/339) 
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Table 4   Summary of available national surveillance data for Chemsex, SDU or CDU among MSM in the UK 
National data 
source 
Description Sexuality 
measure 
Location Population 
assessed 
Recall 
period 
Prevalence Measure 
SDU Chemsex CDU 
Injection 
of 
Chemsex 
drugs 
Event-
level 
National Drug 
Treatment 
Monitoring 
Service 
 (NDTMS) 
(Public Health 
England, 2017a) 
Captures data on 
individuals entering into 
treatment for drug 
addiction. Data 
presented for 2015-
2016 reporting period. 
Self-reported 
sexuality: 
Homosexual 
or Bisexual 
men 
Drug 
treatment 
services 
Gay or bisexual 
men attending 
to treatment for 
drug addiction 
Self-report 
of 
problematic 
substance 
use 
. . 
Amphetamine 34%*         (470/1,363) 
. No 
GHB/GBL 22%* (297/1,363) 
GUMCAD v3 
Pilot 
(Public Health 
England, 2015a) 
Pilot of an 
enhancement of routine 
STI surveillance to 
include behavioural and 
partner notification data 
at 5 SHCs across 
England (July 2015 to 
June 2016 for 8 
consecutive weeks at 
each pilot clinic). 
Self-reported 
sexuality SHC 
MSM attending 
to pilot clinics 
who had a 
GUMCADv3 
record 
submitted and 
reported using 
at least one 
recreational 
drug in the last 3 
months. 
Last sexual 
encounter € 
 
Last 3 
months ± 
43% €     
(65/152) . 
Mephedrone 16% 
±
 
(24/152) 
. Yes 
Methamphetamine 9% 
±
 
(14/152) 
GHB/GBL 16%  
±
 
(24/152) 
Ketamine ȕ 9%  
±
 
(13/152) 
Unlinked 
Anonymous 
Survey of 
People Who 
Inject Drugs 
 
(UAM Survey 
of PWID) 
 
(Heinsbroek et al., in 
press; Public Health 
England, 2017b) 
 
An annual national 
monitoring survey 
collating data on the 
prevalence of BBV’s in 
people who inject 
drugs. Data presented 
for 2013-2016. 
Men 
reporting sex 
with another 
man in the 
last year 
Drug and 
Alcohol 
Services 
MSM attending 
drug services 
who have ever 
injected drugs 
Last Month . . 
Mephedrone 15%** (40/264) 
12%      
(28/237) 
No 
Ketamine ȕ 10%** (25/264) 
6% 
(16/237) 
* Proportions are of all gay or bisexual men attending to treatment for drug addiction during the 2015-2016 reporting period. 
** Non injecting CDU in MSM who report ever injecting drugs during the 2013-16 survey periods. 
β Ketamine is not included in Public Health England’s definition of Chemsex, however prevalence data for ketamine are reported here for international comparison. 
 
Abbreviations: Sexual Health Clinic’s (SHCs), Men who have sex with men (MSM), Blood borne viruses (BBV) 
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Appendix 
 
Appendix 1: PICO Search Strategy for the Chemsex Scoping review 
Search Question:  What is the prevalence of Chemsex and sexualised drug use among men who have sex with 
men in the United Kingdom? 
 
 
 
 
 
 
 
 
 
Appendix 2: PubMed Search strategy 
Sexual*  
AND  
(men who have sex with men   OR     MSM   OR  homosexual*  OR     gay)  
AND  
(GHB OR GBL  OR  Ketamine  OR  Mephedrone  OR  Amphetamine  OR 
Methamphetamine)  
OR 
(Chemsex  OR  Sexualis*  drug  use  OR  Sexualiz*  drug  use  OR         Recreational drug
 OR   Slamming  OR  Slamsex) 
AND 
(men who have sex with men   OR     MSM   OR  homosexual*  OR     gay)  
P Population Men who have sex with 
men 
Gay, MSM, 
Homosexual 
I Intervention or 
Exposure 
Chemsex 
Sexualised drug use (SDU) 
 Slamming 
 Slamsex 
Sexualised drug 
use, slamming, 
Slamsex, 
GHB/GBL, 
mephedrone, 
methamphetamine, 
amphetamine, 
ketamine 
C Comparison None used 
 
. 
O Outcome - Synthesize available 
evidence for the 
prevalence of Chemsex 
and SDU in MSM 
- Identify gaps in the 
available evidence  
. 
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Appendix 3: Study Characteristics 
Study Study Design Purpose of Study Setting Population Chemsex Definition$ 
Bonell 2009 
 
(Bonell et al., 2009) 
Cross 
sectional 
Describe the  prevalence and 
pattern of methamphetamine use 
among MSM both inside and 
outside London 
Online and 
community 
distributed 
(England) 
n= 6155 (MSM)                            
Age range: 14-50+                       
HIV positive: 86/620 (14%) 
. 
Bourne 2014 
 
(A. Bourne et al., 2014) 
Cross 
sectional 
Describe the context, harms and 
motivations for SDU among MSM 
resident in Lambeth, Southwark 
and Lewisham (LSL), London 
Online 
 n=1142 (MSM)                            
Median age: 36 years (range: 
17-76)                                          
HIV positive: 224/1135 (20%)      
(comparator UK EMIS data n 
= 15423) 
Engaging in sexual activities while under the influence of 
drugs. Drugs most commonly associated with Chemsex are 
crystal methamphetamine (hereafter referred to as ‘crystal 
meth’), GHB/GBL, mephedrone and, to a lesser extent, 
cocaine and ketamine. 
Daskalopoulou 
2014 
 
(Daskalopoulou et al., 
2014) 
Cross 
sectional 
Describe the prevalence and 
pattern of illicit drug use in HIV 
positive MSM and the effects these 
drugs have on sexual behaviour. 
8 HIV  
outpatient 
clinics, UK 
n= 2248 (MSM)                            
Median age 46 years (IQR 39-
51)                                               
All HIV positive 
Use of methamphetamine, mephedrone, and GHB, solely 
for facilitating sex (known as Chemsex). 
Dolling, 2016 
 
(Dolling et al., 2016) 
Randomised 
Case Control  
Describe the baseline 
characteristics of MSM recruited 
onto the PROUD study, exploring 
the real world effectiveness of  
PrEP 
13 SHCs in 
England 
n=  540 (MSM)                             
Median age 35 (IQR: 29-43)        
All HIV negative 
ChemSex: Drugs commonly associated with drug use in a 
sexual context (mephedrone, GHB/GBL or crystal 
methamphetamine). 
Elliot 2017 
 
(Elliot et al., 2017) 
Case- Control* 
Characterise illicit drug use in new 
admissions to HIV clinic (case) and 
compare with illicit drug use in 
general admissions to medical 
acute assessment unit (controls)*. 
London 
Hospital  
n=59 (cases)                                
Median age 47 (IQR:34-55)         
HIV positive: 59/59 (100%)          
MSM 42/49 (86%) **       
(The...)  use of drugs for the purpose of sexual 
enhancement ("Chemsex"), particularly methamphetamine, 
mephedrone and GBL/GHB. 
$Definition reported as published. 
* Our synthesis included data from the cases alone as the majority of the control population were non-MSM.  
** All Chemsex and CDU prevalence data are based on data from MSM only. 
 
Abbreviations: Sexual Health Clinic’s (SHCs), Men who have sex with men (MSM), Interquartile range (IQR), European MSM  internet survey (EMIS), Pre-exposure prophylaxis (PrEP), gamma 
butyrolacetone (GBL), gamma hydroxybutyrate (GHB), United Kingdom (UK) Not reported (NR). 
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Fox 2009 
 
(Fox et al., 2009) 
Longitudinal  
Assess the impact of a HIV diagnosis 
on HIV transmission risk behaviour in 
MSM 
HIV clinic, 
London 
n=98 (MSM)                                                
Median age:33 year (range 20-59)             
All HIV positive 
. 
Gilbart 2013 
 
(Gilbart et al., 
2013) 
 
Cross 
sectional  
To investigate the shigellosis 
epidemic in MSM in the UK. UK 
n= 12 (MSM)                                               
HIV Positive: 9/12 (75%)                            
HIV Positive: 225 (19.7%)* 
Mephedrone, ketamine, crystal methamphetamine, and 
GBL… during sexual encounters 
Gilbart 2015 
 
(Gilbart et al., 
2015) 
Cross 
sectional 
To inform control strategies 
undertaken as part of a Shigella 
outbreak among MSM. 
Shigella 
outbreak 
response. 
Case follow-
up interviews 
at a flexible 
location. 
n=34 (MSM)                                                
Median age: 37.5 years (range 21 to 
59)                                                              
HIV Positive: 20/32 (63%) 
Chemsex is the intentional use of drugs that includes 
mephedrone, crystal methamphetamine (crystal meth), 
GBL and GHB. These are taken before or during planned 
activity to sustain, enhance, disinhibit and/or facilitate 
sexual experience. 
Hegazi 2017 
 
(Hegazi et al., 
2017) 
Cross 
sectional 
Analyse associations between SDU, 
STI diagnoses and sexual behaviour 
in MSM accessing SHCs to better 
inform clinical pathways. 
2 SHCs, 
London  
n= 655 (MSM)                                             
Median age: 33 years (range 14-83)         
HIV positive: (7/655) 
Chemsex refers to the use of mephedrone, crystallised 
methamphetamine or GHB/GBL and to a lesser extent 
cocaine and ketamine to facilitate sex. 
Hickson 
2016 
 
(Hickson, Reid, 
Hammond, & 
Weatherburn, 
2016) 
Cross 
sectional 
A needs assessment for gay or 
bisexual men and MSM, assessing 
their alcohol and drug use. 
Online: 
England  
n=15360 (MSM)                                          
Average age: 34.9 years (SD: 13.1)           
HIV Positive: 1382/15360 (9%)       
Three drugs have recently become closely associated 
with sex between men – mephedrone, GHB/GBL and 
crystal meth. Combining sex with use of these drugs has 
become known as Chemsex. 
*Authors note that this HIV prevalence is higher than that in the rest of London and UK. 
 
Abbreviations: Sexual Health Clinic’s (SHCs), Men who have sex with men (MSM), Interquartile range (IQR), gamma butyrolacetone (GBL), gamma hydroxybutyrate (GHB), United Kingdom (UK), 
Sexually transmitted infection (STI), sexualised drug use (SDU), Not reported (NR). 
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Hunter 
2014 
 
(Hunter et al., 
2014) 
Cross 
sectional 
Investigate the pattern of illicit drug use 
in patients and compare drug use 
between MSM and non MSM patients. 
2 hospital SHCs, 
London  
n= 254 (MSM)                                                     
Mean age*: 31 years (SD: 9 years)                    
HIV status: NR 
. 
Ireland 
2017 
 
(Ireland et al., 
2017) 
Cross 
sectional  
Determine the prevalence of newly 
diagnosed hepatitis C virus (HCV) and 
associated risk behaviours among MSM. 
4 SHCs, 
Manchester  
n= 2030 (MSM)                                                   
Median age: 33 years (IQR: 27-42 years)           
39% HIV positive 
. 
Keogh 
2009 
 
(Keogh et al., 
2009)  
Cross 
sectional 
Assess drug and alcohol use in gay/ 
bisexual men and MSM, their resulting 
needs and how these can be met. 
Internet and 
community 
based survey: 
England  
n= 6155                                                               
Median Age: 33 years (range: 14-87)                  
HIV Positive= 10/6155 (16%) 
. 
Kurka 
2015 
 
(Kurka et al., 
2015) 
Cross 
sectional 
Evaluate the improvement of services 
for MSM who use illicit drugs. 
4 clinical 
settings, 
Brighton 
n= 246  (MSM)                                                    
Age: NR                                                              
13% HIV positive 
Club drugs such as mephedrone, GBL/ GBH 
and crystal meth... are associated with high risk 
sexual behaviour (Chemsex) 
Macdonald 
2008 
 
(Macdonald et 
al., 2008) 
Unmatched 
case 
control  
To detect and quantify current risk 
factors for HIV seroconversion among 
gay men seeking repeat tests at sexual 
health clinics. 
Interviews at 7 
SHCs in 
England 
n= 232**                                                              
[ cases (recent HIV diagnosis) n= 75 ]                
[ controls (recent HIV negative) n= 157 ] 
. 
Macdonald 
2014 
 
(Macdonald et 
al., 2014) 
Unmatched 
case 
control 
To identify risk factors for rectal 
lymphogranuloma venereum (rLGV) in 
men who have sex with men (MSM). 
SH, HIV and 
dedicated MSM 
clinics at 6 
hospitals, 
England and 
Scotland  
 n= 233**                                                             
[ cases ( rLGV positive diagnosis) n= 90 ]           
[ controls (rLGV negative diagnosis) n= 143 ]     
Median age: 39 years (range 22 to 56)         
HIV Positive:  156/233 (67%) 
. 
*Mean age is for both MSM and Non MSM (entire sample), mean age of MSM alone NR. Prevalence data for MSM sample alone was included in the data synthesis. 
**For the purpose of determining Chemsex prevalence, the case and control groups were combined. 
 
Abbreviations: Sexual Health Clinic’s (SHCs), Sexual health (SH), Men who have sex with men (MSM), Interquartile range (IQR), gamma butyrolacetone (GBL), gamma hydroxybutyrate (GHB), 
United Kingdom (UK), Sexually transmitted infection (STI), Not reported (NR). 
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MacRae 
2017 
 
(MacRae et al., 
2017) 
Cross 
sectional 
To determine through a 
retrospective case note review if 
national guidelines for taking sexual 
histories, including illicit drug use 
and STI screening were being met. 
Integrated 
HIV and SH 
clinic, 
Manchester   
n= 85 (MSM) 
Age: NR                                                  
All HIV positive 
‘Chemsex’: engaging in sexual activities while under the 
influence of drugs 
Melendez-
Torres 
2016  
 
(Melendez-Torres 
et al., 2016) 
Cross 
sectional 
Characterise demographic and 
socio-sexual risk factors for crystal 
meth use in a national sample of 
UK MSM. 
Internet and 
community 
based 
survey: 
England 
n= 16565                                                 
Median age: 35.1 (SD 13.2)                   
HIV positive: 9% 
Chemsex is the intentional combining of illicit drugs 
(‘chemicals’) with sex in order to facilitate or enhance both 
experiences. The drugs most commonly associated with 
Chemsex in the UK include crystal meth, mephedrone and 
GHB sometimes taken as GBL.  
Melendez-
Torres 
2017 
 
(Melendez-Torres 
et al., 2017) 
Longitudinal  Examine the association between SDU and cAI at encounter level. 
Online 
survey: 
England. 
n=2142 (MSM)                                       
6742 cAI encounters                               
Average age: 42.5 years (SD: 11.9)      
HIV status: NR 
‘Chemsex’ the strategic combining of sex with drug use to 
enhance sexual performance and sensation. 
Mohammed 
2016 
 
(Mohammed et 
al., 2016) 
Cross 
sectional 
Explore the extent of SDU in MSM 
attending to SHCs. 
6 SHCs, 
England 
n= 519 (MSM)                                         
Age: NR                                                  
HIV status: NR 
‘Chemsex’, the use of recreational drugs during sex in MSM.  
Moncrief, 
2014 
 
(Moncrief, 2014) 
Cross 
sectional 
Examine how drug and alcohol 
treatment services could better 
meet the needs of LGBT people. 
LGBT drug 
and alcohol 
support 
service, 
London 
n= 758                                                     
Age: NR                                                  
HIV  status: NR      
‘Chemsex’, the sexualised use of drugs by gay, bisexual, and 
other MSM. The three main presenting drugs are now 
mephedrone, crystal methamphetamine and GHB/GBL 
Ottaway 
2017 (a) 
 
(Ottaway, 
Finnerty, Amlani, 
et al., 2017) 
Cross 
sectional 
Case-
Control 
Evaluate and determine the 
relationship between current SDU 
and STI acquisition locally. 
SHC, 
Brighton 
n= 260 (MSM)**                                      
[ Cases (STI diagnosis) n=130 ]             
[ Controls (no STI diagnosis) n=130 ]    
Median age: 46 years                             
HIV Positive: 40% 
The sexualised use of drugs such as Mephedrone, GHB/GBL 
and crystal methamphetamine, generally known as ‘Chemsex’. 
Ottaway 
2017 (b) 
 
(Ottaway, 
Finnerty, 
Buckingham, et 
al., 2017) 
Cross 
sectional 
Local audit evaluating 
completeness of recreational drug 
history records for MSM accessing 
PEP during two time periods. 
SHC, 
Brighton 
n= 152 (MSM)                                         
[ 2013 -14 period: n=51 ]                        
[ 2015 period: n=101 ]                            
Median age: 31 year (IQR 25-41 
years)                                                   
HIV status: NR 
Chemsex or sexualised recreational drug use.  
**For the purpose of determining Chemsex prevalence, the case and control groups were combined. 
 
Abbreviations: Sexual Health Clinic’s (SHCs), Sexual health (SH), Men who have sex with men (MSM), Interquartile range (IQR), gamma butyrolacetone (GBL), gamma hydroxybutyrate (GHB), 
United Kingdom (UK), Sexually transmitted infection (STI), Post exposure prophylaxis (PEP), lesbian, gay, bisexual & trans people (LGBT), Not reported (NR). 
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Schmidt 
2017 
 
(Schmidt et al., 
2016) 
Cross 
sectional 
Compare patterns of illicit drug use 
among MSM in 44 European urban 
centres (EMIS). 
Online: 44 
European 
cities 
Whole EMIS sample (all countries): 
n= 160952                                                                    
Age: NR                                                                       
HIV Positive: 12.5% 
 
UK EMIS data only:                                                     
n= 8291*      
Age/HIV status: NR   
Combining sex and illicit drugs (an activity referred 
to as ‘Chemsex’), in particular GHB/GBL, ketamine, 
crystal meth, or mephedrone (here called 4-chems) 
Sewell 
2017 
 
(Sewell et al., 
2017) 
Cross 
sectional 
Assess the prevalence and factors 
associated with poly-drug and 
Chemsex drug use, exploring 
associations with sexual behaviour. 
20 SHCs, 
UK 
n= 1484 (MSM)                                                            
Median age: 31.5 years                                               
All HIV negative or undiagnosed 
‘Chemsex’ which relates to the use of certain 
sexually disinhibiting recreational drugs before or 
during sex with the specific purpose of facilitating or 
enhancing sex; namely any combination of crystal 
methamphetamine, mephedrone and GHB/GBL. 
Stuart, 
2013 
 
(Stuart, 
2013) 
Cross 
sectional 
Highlight recent changes in drugs 
use by MSM  
Substance 
misuse 
service, 
London 
n= >8000** (MSM)                                                       
Age: NR                                                                       
HIV status: NR 
Sexualised use of crystal methamphetamine, 
mephedrone and GHB/GBL by MSM populations.  
Thurtle 
2016 
 
(Thurtle et al., 
2016) 
Cross 
sectional 
Provide an overview of illicit drug use 
among SHC attendees in London 
and compare this to existing 
datasets. 
2 SHCs, 
London  
n= 1472 (all attendees)                                                
Mean age: 30.6 years (SD 9 years- all attendees)     
HIV status: NR                                                          
n=339 (MSM)*** 
. 
Ward 2014 
 
(Ward & Lee, 
2014) 
Cross 
sectional 
We looked at HCV antibody testing 
and HCV risk assessment in all MSM 
clinic attenders as part of a Public 
Health England initiative. 
SHC, 
Manchester 
n= 471 (MSM)                                                           
Median age 34 (range 18-71)                                      
54% HIV positive 
. 
*Our synthesis included data from the UK EMIS sample alone.  
**Exact sample size NR.  
*** Our synthesis included prevalence data from this MSM sample alone 
 
Abbreviations: Sexual Health Clinic’s (SHCs), Sexual health (SH), Men who have sex with men (MSM), Interquartile range (IQR), gamma butyrolacetone (GBL), gamma hydroxybutyrate (GHB), 
United Kingdom (UK), Sexually transmitted infection (STI), Post exposure prophylaxis (PEP), lesbian, gay, bisexual & trans people (LGBT), European MSM  internet survey (EMIS), Not reported 
(NR). 
 
 
